A Vision to be the Best
As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you. Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.
Retina Associates
Research-at the forefront of care
Retina Associates has a team of researchers that are focused on advancing and improving the treatment of diseases of the retina, macula and vitreous through clinical studies, teaching, and development of new instruments and techniques. Our physician’s have participated in a multitude of research studies and in many our physicians have served as principal investigators or co-investigators. Current studies that we are involved in are:
Enrolled Studies
1. Ophthotech – A phase 2, Randomized, Double-Masked, Controlled trial to establish the Safety and Efficacy of Intravitreous Injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis 0.5mg/eye in subjects with Neovascular Age-Related Macular Degeneration.
2. Eyetech Inc – A Phase IV, Multi-Center trial to identify whether Intravitreal Injections of Macugen administered every 6 weeks for 48 weeks in subjects with Subfoveal Neovascular Age-Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME) or Retinal Vein Occlusion (RVO) result in adverse effects on the corneal endothelium.
3. Lux BioScience – A Multicenter, Double-Masked, Parallel Group, Placebo-Controlled Study to assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Intermediate, Posterior or Pan-uveitis.
4. Genentech SHORE – A Multicenter, Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema following Retinal Vein Occlusion (BRVO, CRVO, HRVO).
5. PRESERVE (IST through Dr. Gonzalez at Valley Retina in McAllen, TX) – Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease. Intravitreal Injection of Macugen every 4 weeks vs. 6 weeks for patients with DME.
6. Genentech HARBOR – A Phase III, Double Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-Needed Basis in Patients with Subfoveal Neovascular Age-Related Macular Degeneration.
7. Genentech DME – 0.3 mg Ranibizumab, 0.5 mg Ranibizumab, and sham injection for patients with Diabetic Macular Edema ***Amendment 4 for this study includes an extension trial for subjects who complete the 36 month initial study. Subjects can receive monthly treatment if needed with standard dose Lucentis. All of our subjects are eligible to receive Fellow Eye Treatment as well, drug is supplied by Genentech.***
8. Posurdex DME – Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the treatment of Patients with Diabetic Macular Edema.
